AMSTERDAM — IV doses of golimumab resulted in clinically meaningful improvements in skin psoriasis among patients with psoriatic arthritis as early as week 14, regardless of methotrexate use and nail ...
Johnson & Johnson beat Q4 earnings and sales estimates, driven by strong cancer and MedTech growth, and issued a higher 2026 outlook as shares hovered near a 52-week high.
On January 12, 2026, Sanofi announced that the European Commission approved its Teizeild (teplizumab) for delaying progression to stage 3 type ...
On its fourth-quarter earnings conference call on Jan. 21, Johnson & Johnson JNJ announced its financial outlook for 2026, ...
Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dow Jones Dividend Stocks to Buy According to Hedge Funds. On ...
Tahukah Bunda kalau bisa mengecek status pernikahan di situs Kementerian Agama? Begini cara cek status pernikahan di SIMKAH ...
On February 2, 2026, Alvotech announced supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, Australia and New Zealand, further formalized in a Form 6 ...
Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar ...
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Kegiatan ini berlangsung penuh keakraban dan menjadi momentum mempererat persahabatan antarseminari lintas Pulau Flores dan Pulau Timor ...
Zacks Investment Research on MSN
Should you stay invested in J&J stock after Q4 beat & solid guidance?
Johnson & Johnson JNJ delivered strong fourth-quarter 2025 results, with both the top and bottom lines exceeding expectations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results